DiaCarta is a leading precision diagnostic company that specializes in providing comprehensive cancer patient management solutions. We offer a range of products and services, including early detection/screening, diagnostics, therapy selection, and recurrence/resistance monitoring. Our XNA technology, enables us to provide solutions with high sensitivity and affordability, making DiaCarta a one-stop-shop for cancer patient management.
Our proprietary XNA technology allows for sensitive, accurate, and cost-effective detection of genetic alterations using different genomic platforms, positioning us as a leader in the precision diagnostic industry. Our suite of diagnostic products and services, including RadTox™, ColoScape™, and Oncura™, along with our range of infectious disease tests, such as HPV tests and MonkeyPox tests, deliver superior clinical performance and economic value to healthcare providers and patients worldwide.
Headquartered in Pleasanton, California, with subsidiaries in Europe and Asia, we operate 37,000 square feet of CAP-accredited CLIA lab and ISO 13485 certified GMP manufacturing facility, innovative R&D lab, and office space in the US. Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.
HPV mRNA Screening
NGS Targeted Sequencing
CLIA Lab Service
ULTRA-SENSITIVE
XNA Technology
XNA,
ULTRA-SENSITIVE
isobDNA™ Technology
isobDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, isobDNA™ technology does not amplify the DNA or RNA in the samples but amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. isobDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases.
DiaCarta Receives Accreditation by the College of American Pathologists (CAP)
DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta’s leadership and commitment to excellence.
DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.
Dealing with the Respiratory Viruses that Cause Covid-19 or Flu
Influenza and COVID-19: what are they in common? Currently, the two most important respiratory viruses the healthcare authority is paying attention to are SARS-COV-2 (causing COVID-19) and influenza A and B viruses (Flu A and B). The Flu A and B viruses (named by the...
Early Cancer Detection Will Save More Lives
Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...